clinical trial · NCT04856085
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Hepatitis B, ChronicVIR-2218VIR-3434PEG-IFNα
brief summary
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
started
Jul 11, 2021
primary completion
Mar 16, 2026
completion
Mar 16, 2026
last updated
Apr 23, 2026
official title
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol